Trigeminal neuralgia (TN) is a neuropathic pain disorder characterized by severe, lancinating facial pain that is commonly treated with neuropathic medication, percutaneous rhizotomy, and/or microvascular decompression (MVD). Patients who are not found to have distinct arterial compression during MVD present a management challenge. In 2013, the authors reported on a small case series of such patients in whom glycerin was injected intraoperatively into the cisternal segment of the trigeminal nerve. The objective of the authors’ present study was to report their updated experience with this technique to further validate this novel approach.
The authors performed a retrospective analysis of data obtained in patients in whom glycerin was directly injected into the inferior third of the cisternal portion of the trigeminal nerve. Seventy-four patients, including 14 patients from the authors’ prior study, were identified, and demographic information, intraoperative findings, postoperative course, and complications were recorded. Fisher’s exact test, unpaired t-tests, and Kaplan-Meier survival curves using Mantel log-rank test were used to compare the 74 patients with a cohort of 476 patients who received standard MVD by the same surgeon.
The 74 patients who underwent MVD and glycerin injection had an average follow-up of 19.1 ± 18.0 months, and the male/female ratio was 1:2.9. In 33 patients (44.6%), a previous intervention for TN had failed. On average, patients had an improvement in the Barrow Neurological Institute Pain Intensity score from 4.1 ± 0.4 before surgery to 2.1 ± 1.2 after surgery. Pain improvement after the surgery was documented in 95.9% of patients. Thirteen patients (17.6%) developed burning pain following surgery. Five patients developed complications (6.7%), including incisional infection, facial palsy, CSF leak, and hearing deficit, all of which were minor.
Intraoperative injection of glycerin into the trigeminal nerve is a generally safe and potentially effective treatment for TN when no distinct site of arterial compression is identified during surgery or when decompression of the nerve is deemed to be inadequate.
Correspondence Michael Lim: Johns Hopkins Hospital, Baltimore, MD. firstname.lastname@example.org.
INCLUDE WHEN CITING Published online March 8, 2019; DOI: 10.3171/2018.12.JNS182572.
Disclosures Dr. Bettegowda reports being a consultant for DePuy Synthes. Dr. Lim reports being a consultant for Aegenus, BMS, Regeneron, Oncorus, Boston Biomedical, Tocagen, SQZ Technologies, Stryker, and Baxter, and he has received research support from Arbor, Aegenus, Altor, BMS, Immunocellular, Celldex, Accuray, and DNAtrix.
GronsethGCruccuGAlksneJArgoffCBraininMBurchielK: Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology71:1183–11902008
Revuelta-GutierrezRMartinez-AndaJJCollJBCampos-RomoAPerez-PeñaN: Efficacy and safety of root compression of trigeminal nerve for trigeminal neuralgia without evidence of vascular compression. World Neurosurg80:385–3892013
SindouMPChihaMMertensP: Anatomical findings observed during microsurgical approaches of the cerebellopontine angle for vascular decompression in trigeminal neuralgia (350 cases). Stereotact Funct Neurosurg63:203–2071994
Tyler-KabaraECKassamABHorowitzMHUrgoLHadjipanayisCLevyEI: Predictors of outcome in surgically managed patients with typical and atypical trigeminal neuralgia: comparison of results following microvascular decompression. J Neurosurg96:527–5312002
WuMFuXJiYDingWDengDWangY: Microvascular decompression for classical trigeminal neuralgia caused by venous compression: novel anatomic classifications and surgical strategy. World Neurosurg113:e707–e7132018